JP2019517512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517512A5 JP2019517512A5 JP2018563110A JP2018563110A JP2019517512A5 JP 2019517512 A5 JP2019517512 A5 JP 2019517512A5 JP 2018563110 A JP2018563110 A JP 2018563110A JP 2018563110 A JP2018563110 A JP 2018563110A JP 2019517512 A5 JP2019517512 A5 JP 2019517512A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- months
- ctla
- body weight
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 14
- 230000037396 body weight Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000032818 Microsatellite Instability Diseases 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 101150061338 mmr gene Proteins 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims 1
- 101000738901 Homo sapiens PMS1 protein homolog 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 229910015837 MSH2 Inorganic materials 0.000 claims 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims 1
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims 1
- 102100037482 PMS1 protein homolog 1 Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000033607 mismatch repair Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022155878A JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345662P | 2016-06-03 | 2016-06-03 | |
| US62/345,662 | 2016-06-03 | ||
| PCT/US2017/035822 WO2017210637A1 (en) | 2016-06-03 | 2017-06-02 | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155878A Division JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517512A JP2019517512A (ja) | 2019-06-24 |
| JP2019517512A5 true JP2019517512A5 (enExample) | 2020-07-16 |
Family
ID=59078186
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563110A Pending JP2019517512A (ja) | 2016-06-03 | 2017-06-02 | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| JP2022155878A Active JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A Pending JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155878A Active JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A Pending JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11332529B2 (enExample) |
| EP (2) | EP3464373B1 (enExample) |
| JP (3) | JP2019517512A (enExample) |
| KR (3) | KR102702675B1 (enExample) |
| CN (1) | CN109476754A (enExample) |
| ES (1) | ES2897964T3 (enExample) |
| WO (1) | WO2017210637A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20170080697A (ko) | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| SG10201912035YA (en) * | 2015-04-17 | 2020-02-27 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
| PL3334763T3 (pl) | 2015-08-11 | 2024-12-02 | WuXi Biologics Ireland Limited | Nowe przeciwciała anty-pd-1 |
| US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| WO2017210637A1 (en) | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
| CN111770936A (zh) * | 2018-01-12 | 2020-10-13 | 百时美施贵宝公司 | 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| WO2020033283A1 (en) * | 2018-08-09 | 2020-02-13 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc |
| AU2019337547A1 (en) * | 2018-09-13 | 2021-03-18 | Merck Sharp & Dohme Llc | Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
| JP2022527177A (ja) * | 2019-03-28 | 2022-05-31 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| GB201912107D0 (en) * | 2019-08-22 | 2019-10-09 | Amazentis Sa | Combination |
| CN110656179A (zh) * | 2019-10-29 | 2020-01-07 | 至本医疗科技（上海）有限公司 | 免疫敏感性预测的生物标志组成物及用途、试剂盒设备存储介质 |
| CN115569193B (zh) * | 2021-10-09 | 2024-04-02 | 施慧达药业集团(吉林)有限公司 | 戈氏梭菌芽孢联合帕博利珠单抗的应用及治疗结肠癌药物和戈氏梭菌芽孢冻干粉制备方法 |
| EP4612182A1 (en) * | 2022-10-31 | 2025-09-10 | Agenus Inc. | Methods of treating colorectal cancer using an anti-ctla4 antibody |
| TWI898418B (zh) * | 2023-02-09 | 2025-09-21 | 安邦生技股份有限公司 | 用以治療大腸癌的藥學套組及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| DK1212422T3 (da) | 1999-08-24 | 2007-07-02 | Medarex Inc | Humane CTLA-4-antistoffer og anvendelserne deraf |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| EP1340819A1 (en) * | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2005021743A1 (ja) * | 2003-08-29 | 2005-03-10 | Tanaka, Noriaki | 核酸増幅用プライマー及びこれを用いた大腸癌の検査方法 |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| HRP20080053A2 (hr) | 2005-07-01 | 2009-08-31 | Medarex | Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1) |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP5798919B2 (ja) | 2008-08-25 | 2015-10-21 | アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． | Ｐｄ−１アンタゴニストの組成物および使用方法 |
| CA3120172A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| HUE037159T2 (hu) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| FI20115709A0 (fi) | 2011-07-01 | 2011-07-01 | Helsingin Yliopisto | Menetelmä perinnöllisten syöpien diagnosointiin |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| ES2845609T3 (es) | 2013-05-02 | 2021-07-27 | Anaptysbio Inc | Anticuerpos dirigidos contra muerte programada-1 (PD-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| AU2015210886A1 (en) * | 2014-01-29 | 2016-09-01 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| KR20170080697A (ko) * | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| CN106714836A (zh) | 2015-06-05 | 2017-05-24 | H·李·莫菲特癌症中心研究有限公司 | Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗 |
| WO2017210637A1 (en) | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
| WO2018183408A1 (en) * | 2017-03-31 | 2018-10-04 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
-
2017
- 2017-06-02 WO PCT/US2017/035822 patent/WO2017210637A1/en not_active Ceased
- 2017-06-02 KR KR1020237010151A patent/KR102702675B1/ko active Active
- 2017-06-02 JP JP2018563110A patent/JP2019517512A/ja active Pending
- 2017-06-02 EP EP17731359.0A patent/EP3464373B1/en not_active Revoked
- 2017-06-02 US US16/306,290 patent/US11332529B2/en active Active
- 2017-06-02 ES ES17731359T patent/ES2897964T3/es active Active
- 2017-06-02 CN CN201780048328.2A patent/CN109476754A/zh active Pending
- 2017-06-02 EP EP21197402.7A patent/EP3988570A1/en active Pending
- 2017-06-02 KR KR1020187038115A patent/KR102515509B1/ko active Active
- 2017-06-02 KR KR1020247029228A patent/KR20240134249A/ko active Pending
-
2022
- 2022-04-19 US US17/724,399 patent/US20220356254A1/en not_active Abandoned
- 2022-09-29 JP JP2022155878A patent/JP7721494B2/ja active Active
-
2024
- 2024-07-29 US US18/787,822 patent/US20250026831A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093572A patent/JP2025143276A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517512A5 (enExample) | ||
| CN108289892B (zh) | 治疗组合物、组合和使用方法 | |
| JP2018500332A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2022050618A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| TWI890661B (zh) | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 | |
| JP2018522887A5 (enExample) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2018516966A5 (enExample) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| JP2018516969A5 (enExample) | ||
| JP2019519499A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2019515008A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2016536314A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| JP2017502017A5 (enExample) | ||
| JP2019517512A (ja) | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 | |
| JP2012102122A5 (enExample) | ||
| JP2019517511A5 (enExample) | ||
| JP2019517498A5 (enExample) |